The Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Inflammatory Bowel Disease

Abstract Background Inflammatory bowel disease (IBD) is associated with a high prevalence of comorbid depressive and anxiety disorders. A significant proportion of IBD patients with comorbid psychiatric disorders remain undiagnosed and untreated, but factors associated with diagnosis are unknown. We evaluated the prevalence of undiagnosed depression and anxiety in an IBD cohort, along with the associated demographic and clinical characteristics. Methods We obtained data from the enrollment visit of a cohort study of psychiatric comorbidity in immune-mediated diseases including IBD. Each participant underwent a Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID) to identify participants who met lifetime criteria for a diagnosis of depression or anxiety. Those with a SCID-based diagnosis were classified as diagnosed or undiagnosed based on participant report of a physician diagnosis. Results Of 242 eligible participants, 97 (40.1%) met SCID criteria for depression, and 74 (30.6%) met criteria for anxiety. One-third of participants with depression and two-thirds with anxiety were undiagnosed. Males were more likely to have an undiagnosed depressive disorder (odds ratio [OR], 3.36; 95% confidence interval [CI], 1.28–8.85). Nonwhite participants were less likely to have an undiagnosed anxiety disorder (OR, 0.17; 95% CI, 0.042–0.72). Conclusion Our findings highlight the importance of screening for depression and anxiety in patients with IBD, with particular attention to those of male sex and with a lower education level.

Download Full-text

Validity and reliability of the health-related questionnaire IBDQ-32 in Mexican patients with inflammatory bowel disease

Gastroenterología y Hepatología ◽

10.1016/j.gastrohep.2021.03.002 ◽

2021 ◽

Author(s):

Mónica R. Zavala-Solares ◽

Lucero Salazar-Salas ◽

Jesus K. Yamamoto-Furusho

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Validity And Reliability ◽

Health Related ◽

Inflammatory Bowel ◽

Mexican Patients

Download Full-text

Prevalence of Anxiety and Depression in Patients with Inflammatory Bowel Disease

Canadian Journal of Gastroenterology and Hepatology ◽

10.1155/2017/6496727 ◽

2017 ◽

Vol 2017 ◽

pp. 1-6 ◽

Cited By ~ 50

Author(s):

Glynis Byrne ◽

Greg Rosenfeld ◽

Yvette Leung ◽

Hong Qian ◽

Julia Raudzus ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Multivariable Analysis ◽

Significant Proportion ◽

Mental Illnesses ◽

Self Report ◽

Anxiety And Depression ◽

Depression And Anxiety ◽

Psychiatric Interview ◽

Inflammatory Bowel

Background. Inflammatory bowel disease (IBD) patients are not routinely screened for depression and anxiety despite knowledge of an increased prevalence in people with chronic disease and negative effects on quality of life. Methods. Prevalence of anxiety and depression was assessed in IBD outpatients through retrospective chart review. The presence of anxiety and/or depression was determined using the Patient Health Questionnaire-9 and Generalized Anxiety Disorder-7 self-report questionnaires or by diagnosis through psychiatric interview. Patient demographics, disease characteristics, and medication information were also collected. Multivariable analysis was used to determine associations between patient factors and depression and anxiety. Results. 327 patient charts were reviewed. Rates of depression and anxiety were found to be 25.8% and 21.2%, with 30.3% of patients suffering from depression and/or anxiety. Disease activity was found to be significantly associated with depression and/or anxiety (p=0.01). Females were more likely to have anxiety (p=0.01). Conclusion. A significant proportion of IBD patients suffer from depression and/or anxiety. The rates of these mental illnesses would justify screening and referral for psychiatric treatment in clinics treating this population. Patients with active disease are particularly at risk for anxiety and depression.

Download Full-text

Controversies surrounding the comorbidity of depression and anxiety in inflammatory bowel disease patients

Inflammatory Bowel Diseases ◽

10.1002/ibd.20062 ◽

2007 ◽

Vol 13 (2) ◽

pp. 225-234 ◽

Cited By ~ 101

Author(s):

Antonina A. Mikocka-Walus ◽

Deborah A. Turnbull ◽

Nicole T. Moulding ◽

Ian G. Wilson ◽

Jane M. Andrews ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Depression And Anxiety ◽

Inflammatory Bowel

Download Full-text

The Symptoms and Medications of Patients with Inflammatory Bowel Disease in Hubei Province after COVID-19 Epidemic

Journal of Immunology Research ◽

10.1155/2020/2847316 ◽

2020 ◽

Vol 2020 ◽

pp. 1-7

Author(s):

Huan Wang ◽

Lei Tu ◽

Ying Li ◽

Tao Bai ◽

Kaifang Zou ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Online Survey ◽

Gastrointestinal Symptoms ◽

Life Quality ◽

Scoring Systems ◽

Hubei Province ◽

Depression And Anxiety ◽

Psychological Issues ◽

Inflammatory Bowel

Objectives. The COVID-19 epidemic triggered by coronavirus SARS-CoV-2 is rapidly spreading around the globe. This study is aimed at finding out the suspected or confirmed SARS-CoV-2 infection in patients with inflammatory bowel disease (IBD) in Hubei province, China. We also investigated symptoms, medications, life quality, and psychological issues of IBD patients under the ongoing pandemic. Methods. We conducted a self-reported questionnaire survey via an online survey platform. SARS-CoV-2 infection-related data was collected from IBD patients. The status quo of medications and symptoms of the subjects were investigated. Life quality, depression, and anxiety were measured by clinical questionnaires and rated on scoring systems. Results. A total of 204 IBD patients from Hubei province were included in this study. No suspected or confirmed SARS-CoV-2 infection case was found in this study. As a result of city shutdown, two-thirds of the patients (138/204) in our series reported difficulty in accessing medicines and nearly half of them (73/138) had to discontinue medications. Apart from gastrointestinal symptoms, systemic symptoms were common while respiratory symptoms were rare in the cohort. Though their quality of life was not significantly lowered, depression and anxiety were problems that seriously affected them during the COVID-19 epidemic. Conclusions. Inaccessibility to medications is a serious problem for IBD patients after city shutdown. Efforts have to be made to address the problems of drug withdrawal and psychological issues that IBD patients suffer from during the COVID-19 outbreak.

Download Full-text

P314 C-Reactive protein is associated with depression and anxiety in patients with inflammatory bowel disease

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjz203.443 ◽

2020 ◽

Vol 14 (Supplement_1) ◽

pp. S311-S311

Author(s):

T Rodriguez ◽

J Karpin ◽

C Traboulsi ◽

V Rai ◽

D Rubin

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Patient Characteristics ◽

Adaptive Testing ◽

Prior History ◽

Depression And Anxiety ◽

C Reactive Protein ◽

Reactive Protein ◽

Severity Scores ◽

Inflammatory Bowel

Abstract Background Depression and anxiety are comorbidities of inflammatory bowel disease (IBD). Though previous studies have proposed a relationship between anxiety, depression and IBD, causality and directionality are unknown. We used a novel computerised adaptive testing technology to screen IBD patients for depression and anxiety and compared the screening results to recent measures of C-reactive protein (CRP). Methods Consecutive patients at our tertiary IBD clinic were asked to complete the validated CAT-MH™ survey from Adaptive Testing Technologies (Chicago, IL); we then reviewed disease and patient characteristics. CRP measures from within 6 months of survey administration were used and levels ≥5 mg/l were considered positive. Patients who are CRP non-reactive were excluded. Pearson Chi-Square test was used to assess correlation. Results 134 patients (75 women, 112 Caucasian, 84 Crohn’s disease) participated in the study, 85 of whom had no prior history of psychiatric disorders. We identified 51 patients with depression (46 mild, 3 moderate, 2 severe) and 36 subjects with anxiety (24 mild, 10 moderate, 2 severe). Of the 134 patients recruited for this study, 57 had CRP reported. Median time between CRP measurement and CAT-MH™ administration was 2 days (IQR = 70). Categorical analysis stratified patients with positive and negative CRP who are also positive for depression and/or anxiety. Compared with patients with negative CRP values, patients with positive CRP were more likely to also test positive for depression and anxiety. These results were statistically significant for depression (p = 0.008) and nearly significant for anxiety (p = 0.058) (Figure 1). Quartile analysis of the 21 patients with elevated CRP levels revealed an increasing trend of average depression and anxiety severity scores. However, this correlation was lost when CRP >21 mg/l (Figure 2). Conclusion We illustrate the significant association between CRP and depression and anxiety severity scores on the CAT-MH™ survey. These findings suggest a positive relationship between inflammation and depression and anxiety in IBD patients. Physicians should consider patients with elevated CRP levels at risk for these mental health conditions.

Download Full-text